文献速递系统性红斑狼疮

双靶向BCMA-CD19 CAR-T治疗系统性红斑狼疮的单细胞与免疫组库分析

Dual-Targeting BCMA-CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution.
PubMed 文献 · Arthritis Rheumatol · 2026-04-02

该研究对5例SLE患者接受BCMA-CD19双靶向CAR-T后外周血单个核细胞进行单细胞RNA测序及BCR/TCR测序,并与7例CD19单靶向CAR-T患者和3例健康对照的公共数据整合分析(共15例、176,182个单细胞)。结果显示双靶向CAR-T诱导更深的B细胞谱系(包括浆细胞谱系)耗竭,BCR组库向IGHM主导的初始B细胞偏移,临床SLEDAI显著下降。

要点

  • 双靶向CAR-T较CD19单靶向更深度耗竭浆细胞谱系集群。
  • 双靶向CAR-T更强抑制RIG-I/MDA5和I型干扰素转录程序。
  • BCR组库向IGHM主导的初始B细胞偏移,SLEDAI由9.6降至2.4。

核心结论

  • BCMA-CD19双靶向CAR-T与更深的浆细胞谱系耗竭相关,并倾向于更显著逆转SLE相关分子特征。
  • 该探索性发现提示双靶向可能实现更全面的体液免疫重置,但需进一步直接比较研究确定临床优效性。

研究设计与样本

  • 对5例SLE患者输注前及外周B细胞重建后(中位90天)行单细胞RNA测序及BCR/TCR平行测序。
  • 整合7例CD19单靶向CAR-T治疗的SLE患者和3例健康对照的公共数据进行比较分析,共15例受试者、176,182个单细胞。

主要发现

  • 双靶向CAR-T诱导B细胞谱系显著耗竭,包括CD19治疗后持续存在的浆细胞谱系集群。
  • 双靶向队列中集群2从10.70%降至2.67%,集群3从9.55%降至3.12%;单靶向 comparator 中集群3从6.78%升至12.19%。
  • 双靶向对B细胞中RIG-I/MDA5和I型干扰素转录程序的抑制强于单靶向治疗。
  • BCR组库向IGHM主导(49.83%-89.19%,P < 0.05)、初始B细胞偏移,预富集的类别转换克隆收缩,多样性恢复至健康样谱。
  • 临床改善显著,平均SLEDAI从9.6降至2.4(P < 0.05),与分子变化平行。

关键数值与推荐

  • 双靶向队列集群2从10.70%降至2.67%,集群3从9.55%降至3.12%。
  • 单靶向 comparator 中集群3从6.78%升至12.19%。
  • BCR组库IGHM主导比例49.83%-89.19%(P < 0.05)。
  • 平均SLEDAI从9.6降至2.4(P < 0.05)。

临床怎么用

  • 双靶向BCMA-CD19 CAR-T可能通过更全面耗竭浆细胞谱系和抑制I型干扰素通路实现更深的体液免疫重置。
  • 该探索性结果支持在SLE中进一步开展直接比较研究以评估双靶向CAR-T的临床优效性。

局限性

  • 样本量小(双靶向5例,总15例),为探索性研究。
  • 与单靶向及健康对照的比较基于公共数据集整合,非头对头直接比较。
  • 随访时间点为中位90天,缺乏长期免疫重建动态数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate peripheral immune reconstitution following BCMA-CD19 dual-targeting CAR-T therapy in patients with systemic lupus erythematosus (SLE). METHODS: Single-cell RNA sequencing and parallel B cell receptor (BCR) and T cell receptor sequencing were performed on peripheral blood mononuclear cells from five patients with SLE before infusion and after peripheral B cell reconstitution (median 90 days postinfusion). These data were integrated with public datasets from seven patients with SLE treated with CD19 single-targeting CAR-T and three healthy controls for comparative analysis (total N = 15 subjects; 176,182 single cells analyzed). RESULTS: Dual-targeting CAR-T induced marked depletion of B-lineage populations, including plasma-lineage clusters that persisted after CD19 therapy. Specifically, cluster 2 decreased from 10.70% to 2.67% and cluster 3 from 9.55% to 3.12% in the dual-targeting cohort, whereas cluster 3 increased (6.78%-12.19%) in the single-targeting comparator. In B cells, dual targeting produced greater suppression of RIG-I/MDA5 and type I interferon transcriptional programs than single-targeting therapy. BCR repertoires shifted toward an IGHM-dominant (49.83%-89.19%, P < 0.05), naïve-biased profile, with contraction of pre-enriched class-switched clones and restoration of diversity toward healthy-like profiles. Clinical improvement was significant (mean SLE Disease Activity Index decreased from 9.6 to 2.4, P < 0.05), paralleling these molecular changes. CONCLUSION: BCMA-CD19 dual CAR-T therapy was associated with deeper depletion of plasma-lineage compartments and a tendency toward more pronounced reversal of SLE-associated molecular signatures. This exploratory finding suggests a potential advantage of dual targeting in achieving a more comprehensive humoral reset in SLE, which warrants further direct comparative studies to determine clinical superiority.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. He Z, Wang W, Li Q, et al. Dual-Targeting BCMA-CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution. Arthritis Rheumatol. 2026. PMID: 41787704. doi:10.1002/art.70117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。